2017 Sec 1 Green Book

43. Kristo A, Uhari M, Luotonen J, Ilkko E,

Koivunen P, Alho OP. Cefuroxime axetil

versus placebo for children with acute

respiratory infection and imaging evi-

dence of sinusitis: a randomized, con-

trolled trial.

Acta Paediatr

. 2005;94(9):

1208

–

1213

44. Hoberman A, Paradise JL, Rockette HE,

et al. Treatment of acute otitis media in

children under 2 years of age.

N Engl J

Med

. 2011;364(2):105

–

115

45. Tahtinen PA, Laine MK, Huovinen P, Jalava

J, Ruuskanen O, Ruohola A. A placebo-

controlled trial of antimicrobial treat-

ment for acute otitis media.

N Engl J Med

2011;364(2):116

–

126

46. Gordts F, Abu Nasser I, Clement PA,

Pierard D, Kaufman L. Bacteriology of the

middle meatus in children.

Int J Pediatr

Otorhinolaryngol

. 1999;48(2):163

–

167

47. Parsons DS, Wald ER. Otitis media and

sinusitis: similar diseases.

Otolaryngol

Clin North Am

. 1996;29(1):11

–

48. Revai K, Dobbs LA, Nair S, Patel JA, Grady

JJ, Chonmaitree T. Incidence of acute oti-

tis media and sinusitis complicating up-

per respiratory tract infection: the effect

of age.

Pediatrics

. 2007;119(6). Available at:

www.pediatrics.org/cgi/content/full/119/6/

e1408

49. Klein JO, Bluestone CD.

Textbook of Pedi-

atric Infectious Diseases

. 6th ed. Phila-

delphia, PA: Saunders; 2009

50. Casey JR, Adlowitz DG, Pichichero ME. New

patterns in the otopathogens causing

acute otitis media six to eight years after

introduction of pneumococcal conjugate

vaccine.

Pediatr Infect Dis J

. 2010;29(4):

304

–

309

51. Brook I, Gober AE. Frequency of recovery

of pathogens from the nasopharynx of

children with acute maxillary sinusitis

before and after the introduction of vac-

cination with the 7-valent pneumococcal

vaccine.

Int J Pediatr Otorhinolaryngol

2007;71(4):575

–

579

52. Wald ER. Microbiology of acute and

chronic sinusitis in children.

J Allergy Clin

Immunol

. 1992;90(3 pt 2):452

–

456

53. Centers for Disease Control and Pre-

vention. Effects of new penicillin suscep-

tibility breakpoints for

Streptococcus

pneumoniae

—

United States, 2006-2007.

MMWR Morb Mortal Wkly Rep

. 2008;57

(50):1353

–

1355

54. Centers for Disease Control and Preven-

tion. Active Bacterial Core Surveillance

(ABCs): Emerging Infections Program Net-

work. 2011. Available at: www.cdc.gov/abcs/

reports-

ndings/survreports/spneu09.html.

Accessed November 6, 2012

55. Garbutt J, St Geme JW, III, May A, Storch GA,

Shackelford PG. Developing community-

speci

c recommendations for

rst-line

treatment of acute otitis media: is high-

dose amoxicillin necessary?

Pediatrics

2004;114(2):342

–

347

56. Harrison CJ, Woods C, Stout G, Martin B,

Selvarangan R. Susceptibilities of

Haemo-

philus in

uenzae, Streptococcus pneumo-

niae

including serotype 19A,

and

Moraxella catarrhalis

paediatric isolates

from 2005 to 2007 to commonly used

antibiotics.

J Antimicrob Chemother

. 2009;

63(3):511

–

519

57. Critchley IA, Jacobs MR, Brown SD,

Traczewski MM, Tillotson GS, Janjic N.

Prevalence of serotype 19A Streptococcus

pneumoniae among isolates from U.S.

children in 2005-2006 and activity of far-

openem.

Antimicrob Agents Chemother

2008;52(7):2639

–

2643

58. Jacobs MR, Good CE, Windau AR, et al. Ac-

tivity of ceftaroline against recent emerging

serotypes of

Streptococcus pneumoniae

the United States.

Antimicrob Agents Che-

mother

. 2010;54(6):2716

–

2719

59. Tristram S, Jacobs MR, Appelbaum PC.

Antimicrobial resistance in

Haemophilus

uenzae. Clin Microbiol Rev

. 2007;20(2):

368

–

389

60. Levine OS, Farley M, Harrison LH, Lefkowitz

L, McGeer A, Schwartz B. Risk factors for

invasive pneumococcal disease in chil-

dren: a population-based case-control

study in North America.

Pediatrics

. 1999;

103(3). Available at:

www.pediatrics.org/

cgi/content/full/103/3/e28

61. Seikel K, Shelton S, McCracken GH Jr.

Middle ear

uid concentrations of amox-

icillin after large dosages in children with

acute otitis media.

Pediatr Infect Dis J

1997;16(7):710

–

711

62. Cohen R, Navel M, Grunberg J, et al. One

dose ceftriaxone vs.

ten days of

amoxicillin/clavulanate therapy for acute

otitis media: clinical ef

cacy and change

in nasopharyngeal

ora.

Pediatr Infect Dis

. 1999;18(5):403

–

409

63. Green SM, Rothrock SG. Single-dose in-

tramuscular ceftriaxone for acute otitis

media in children.

Pediatrics

. 1993;91(1):

–

64. Leibovitz E, Piglansky L, Raiz S, Press J,

Leiberman A, Dagan R. Bacteriologic and

clinical ef

cacy of one day vs. three day

intramuscular ceftriaxone for treatment

of nonresponsive acute otitis media in

children.

Pediatr Infect Dis J

. 2000;19(11):

1040

–

1045

65. DePestel DD, Benninger MS, Danziger L,

et al. Cephalosporin use in treatment of

patients with penicillin allergies.

J Am

Pharm Assoc

. 2008;48(4):530

–

540

66. Pichichero ME. A review of evidence sup-

porting the American Academy of Pediat-

rics recommendation for prescribing

cephalosporin antibiotics for penicillin-

allergic patients.

Pediatrics

. 2005;115(4):

1048

–

1057

67. Pichichero ME, Casey JR. Safe use of

selected cephalosporins in penicillin-

allergic patients: a meta-analysis.

Oto-

laryngol Head Neck Surg

. 2007;136(3):

340

–

347

68. Park MA, Koch CA, Klemawesch P, Joshi A,

Li JT. Increased adverse drug reactions to

cephalosporins in penicillin allergy

patients with positive penicillin skin test.

Int Arch Allergy Immunol

. 2010;153(3):

268

–

273

69. Jacobs MR. Antimicrobial-resistant Strep-

tococcus pneumoniae: trends and man-

agement.

Expert Rev Anti Infect Ther

. 2008;

6(5):619

–

635

70. Chow AW, Benninger MS, Brook I, et al;

Infectious Diseases Society of America.

IDSA clinical practice guideline for acute

bacterial rhinosinusitis in children and

adults.

Clin Infect Dis

. 2012;54(8):e72

–

e112

71. Brook I, Gober AE. Resistance to anti-

microbials used for therapy of otitis media

and sinusitis: effect of previous antimi-

crobial therapy and smoking.

Ann Otol

Rhinol Laryngol

. 1999;108(7 pt 1):645

–

647

72. Brook I, Gober AE. Antimicrobial re-

sistance in the nasopharyngeal

ora of

children with acute maxillary sinusitis

and maxillary sinusitis recurring after

amoxicillin therapy.

J Antimicrob Chemo-

ther

. 2004;53(2):399

–

402

73. Dohar J, Canton R, Cohen R, Farrell DJ,

Felmingham D. Activity of telithromycin

and comparators against bacterial

pathogens isolated from 1,336 patients

with clinically diagnosed acute sinusitis.

Ann Clin Microbiol Antimicrob

. 2004;3(3):

–

74. Jacobs MR, Bajaksouzian S, Zilles A, Lin G,

Pankuch GA, Appelbaum PC. Susceptibili-

ties of

Streptococcus pneumoniae

and

Haemophilus in

uenzae

to 10 oral anti-

microbial agents based on pharmacody-

namic parameters: 1997 U.S. surveillance

study.

Antimicrob Agents Chemother

1999;43(8):1901

–

1908

75. Jacobs MR, Felmingham D, Appelbaum PC,

Gruneberg RN. The Alexander Project

1998-2000: susceptibility of pathogens

isolated from community-acquired re-

spiratory tract infection to commonly

used antimicrobial agents.

J Antimicrob

Chemother

. 2003;52(2):229

–

246

PEDIATRICS Volume 132, Number 1, July 2013

FROM THE AMERICAN ACADEMY OF PEDIATRICS

113